PF-Atlas › Clinical Trials › NCT06526923
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis
SP-101 and doxorubicin Cohort 1 · Phase 1
Registry ID
NCT06526923
Phase
Phase 1
Status
Recruiting
Drug / intervention
SP-101 and doxorubicin Cohort 1
Sponsor
Spirovant Sciences, Inc.
Start
2024-09-16
About this trial
SP-101 and doxorubicin Cohort 1 is evaluated in NCT06526923, a Phase 1 idiopathic pulmonary fibrosis study sponsored by Spirovant Sciences, Inc.. Current status: Recruiting.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT06526923 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.